US Patent Issued to BLISS BIOPHARMACEUTICAL (HANGZHOU) on April 21 for "Modified EGFR antibody with reduced affinity, drug conjugate, and use thereof" (Chinese Inventors)

ALEXANDRIA, Va., April 21 -- United States Patent no. 12,605,457, issued on April 21, was assigned to BLISS BIOPHARMACEUTICAL (HANGZHOU) Co. LTD. (Hangzhou, China).

"Modified EGFR antibody with reduced affinity, drug conjugate, and use thereof" was invented by Bing Xia (Zhejiang, China), Yuhong Zhou (Zhejiang, China), Ziping Wei (Zhejiang, China), Lixia Cao (Zhejiang, China) and Fangdun Jiang (Zhejiang, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides isolated antibodies that bind to the human EGFR protein, and ADCs of the antibodies. Pharmaceutical compositions including the antibodies and ADCs, and methods of treating cancer are also provided."

The patent was filed on No...